Inventor · disambiguated record
Rita Mitnacht-Kraus
Also filed as: MITNACHT-KRAUS RITA
16 granted patents·7 pending applications·85 citations·filing 2009–2024
92Inventor score
Top patents by PatentIndex Score
23 records- 0195US8946388B2Monoclonal antibodies for treatment of cancerSAHIN UGUR·Filed 2009·Granted Feb 3, 2015·41 cites·16 claims
- 0291US10813996B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Oct 27, 2020·4 cites·18 claims
- 0390US9770487B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 26, 2017·11 cites·30 claims
- 0489US10053512B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Aug 21, 2018·6 cites·34 claims
- 0589US9512232B2Antibodies against Claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Dec 6, 2016·9 cites·11 claims
- 0688US10314890B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Jun 11, 2019·5 cites·40 claims
- 0787US2024309108A1Antibodies against claudin 18.2 useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 0885US2024335533A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 0983US9433675B2Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Sep 6, 2016·5 cites·23 claims
- 1083US2024209079A1Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 1181US2024091312A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2023·Application pending·0 cites
- 1280US11541127B2Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 3, 2023·2 cites·28 claims
- 1379US10022444B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Jul 17, 2018·2 cites·32 claims
- 1478US11919951B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2022·Granted Mar 5, 2024·0 cites·21 claims
- 1573US11826402B2Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinomaASTELLAS PHARMA INC·Filed 2020·Granted Nov 28, 2023·0 cites·7 claims
- 1672US12059464B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerASTELLAS PHARMA INC·Filed 2020·Granted Aug 13, 2024·0 cites·22 claims
- 1771US10946069B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerASTELLAS PHARMA INC·Filed 2019·Granted Mar 16, 2021·0 cites·20 claims
- 1870US11976130B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2018·Granted May 7, 2024·0 cites·16 claims
- 1970US2023270878A1Drug conjugates comprising antibodies against claudin 18.2GANYMED PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2068US11279757B2Antibodies useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2018·Granted Mar 22, 2022·0 cites·20 claims
- 2149US2015132253A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 2248US2018258180A1Combination therapy involving antibodies against claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Application pending·0 cites
- 2346US10596256B2Monoclonal anti-GT 468 antibodies for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Mar 24, 2020·0 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Rita Mitnacht-Kraus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →